Strs Ohio Sells 2,589 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Strs Ohio trimmed its stake in Regeneron by 7.3% in Q4, selling 2,589 shares and leaving it with 32,996 shares valued at about $25.47 million.
• Regeneron beat Q1 expectations — revenue rose ~19% to $3.61 billion and EPS was $9.47 vs. a $8.91 consensus — and the company announced a $3 billion share buyback and a quarterly dividend of $0.94 per share.
• Analyst and investor picture is mixed: the stock has a consensus rating of "Moderate Buy" with an average target of $826.59, institutional ownership is ~83%, and insiders have sold 3,774 shares in the past 90 days (insiders own 7.02%).

Strs Ohio cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 32,996 shares of the biopharmaceutical company's stock after selling 2,589 shares during the period. Strs Ohio's holdings in Regeneron Pharmaceuticals were worth $25,469,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. Robeco Institutional Asset Management B.V. increased its stake in Regeneron Pharmaceuticals by 153.4% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company's stock worth $67,969,000 after buying an additional 73,176 shares in the last quarter. PGGM Investments increased its stake in Regeneron Pharmaceuticals by 9.7% during the 3rd quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company's stock worth $52,057,000 after buying an additional 8,187 shares in the last quarter. Sound Shore Management Inc CT purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $64,677,000. Rakuten Investment Management Inc. purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $33,121,000. Finally, Ellerson Group Inc. ADV increased its stake in Regeneron Pharmaceuticals by 49.2% during the 3rd quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company's stock worth $4,556,000 after buying an additional 2,671 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 0.8%

REGN opened at $701.42 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The stock has a market capitalization of $74.15 billion, a PE ratio of 17.09, a P/E/G ratio of 1.61 and a beta of 0.30. The business's 50 day moving average price is $756.81 and its 200 day moving average price is $736.41. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.39 and a current ratio of 3.57.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping analysts' consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company had revenue of $3.61 billion for the quarter, compared to analysts' expectations of $3.48 billion. During the same period in the prior year, the firm earned $8.22 earnings per share. The firm's revenue was up 19.0% compared to the same quarter last year. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 36.05 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Wednesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is 9.16%.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported a stronger-than-expected Q1 (revenue up ~19%, EPS beat) and announced a $3 billion share buyback — fundamentals and the buyback are clear upside catalysts for shareholder value. Regeneron reports strong Q1 CY2026
• Positive Sentiment: Guggenheim raised its price target to $995 and retained a Buy — that implies sizable upside and supports sentiment among growth/value investors. Guggenheim raises REGN target to $995
• Neutral Sentiment: Zacks highlights REGN as a long-term value pick — supportive narrative for buy-and-hold investors but not an immediate price catalyst. Why Regeneron is a Top Value Stock
• Neutral Sentiment: Several banks trimmed price targets modestly (Barclays, Truist, Wells Fargo) but largely kept positive/market-weight ratings — suggests analysts revised models after Q1 details but remain constructive overall. Analyst PT changes after Q1
• Negative Sentiment: Royal Bank of Canada cut its target to $762 and moved to a "sector perform" stance — a more cautious view that likely weighed on intraday selling pressure. RBC lowers REGN target to $762
• Negative Sentiment: Coverage and model cuts followed the Q1 release despite the beat; investors focused on items such as a 10% drop in net income year-over-year (even as revenue rose), which may have trimmed near-term expectations. Regeneron Q1 2026 net income falls 10%
• Negative Sentiment: Market reaction: shares fell despite the beat — coverage (Seeking Alpha) points to investor disappointment or guidance/forward assumptions as the reason for the drop. That momentum explains today's weaker price action. Regeneron drops despite Q1 beat

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of the company's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the company's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the transaction, the director owned 17,803 shares in the company, valued at $13,860,169.59. This trade represents a 0.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,774 shares of company stock worth $2,942,738 over the last ninety days. Corporate insiders own 7.02% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have commented on REGN. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $801.00 to $796.00 and set a "buy" rating for the company in a research note on Thursday. Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an "equal weight" rating in a research note on Friday, April 10th. Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $825.00 to $800.00 and set an "equal weight" rating on the stock in a report on Thursday. JPMorgan Chase & Co. boosted their target price on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an "overweight" rating in a report on Monday, February 2nd. Finally, Bank of America upgraded Regeneron Pharmaceuticals from an "underperform" rating to a "buy" rating and boosted their target price for the stock from $627.00 to $860.00 in a report on Wednesday, January 7th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $826.59.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.